Filing Flows › Health Care › Nutra Pharma (NPHC)
Nutra Pharma (NPHC) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 19, 2026 · Nutra Pharma (NPHC) Q2 2026 earnings results →
Q2 2026 Revenue down 59% year over year to $34K
Nutra Pharma made $34K in Q2 2026 (-59% Y/Y). Operating margin n/m, net loss $3.9M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 19, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $34K in Q2 2026, down 59% year over year and up 26% from the previous quarter.
Gross margin was 94.7%, up 19.6 points from Q2 2025. Operating costs exceeded revenue by $435K, an operating margin of -1263.6%. Operating expenses grew 32% against a revenue fall of 59%. The quarter ended with a net loss of $3.9M, wider than the previous quarter's $460K loss. Net interest and other expense of $3.5M was the main reason.
Operating cash flow was −$251K. Non-cash charges added back $2K of depreciation and $4K of share-based compensation. Working capital and other items added $3.7M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 19, 2026 | $34K | -59% | n/m | −$3.9M | −$251K |
| Q1 2026 | 10-Q | May 29, 2026 | $27K | -63% | n/m | −$460K | −$328K |
| Q4 2025 | 10-K | May 20, 2026 | $29K | -65% | n/m | −$489K | −$220K |
| Q3 2025 | 10-Q | Apr 6, 2026 | $70K | -6% | -506.9% | −$524K | −$251K |
| Q2 2025 | 10-Q | Mar 25, 2026 | $85K | +64% | -343.7% | $370K | −$288K |
| Q1 2025 | 10-Q | Mar 11, 2026 | $74K | +96% | -472.9% | −$1.4M | −$405K |
| Q4 2024 | 10-K | Feb 17, 2026 | $82K | +74% | -218.5% | −$231K | −$178K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Nutra Pharma
Nutra Pharma is a biopharmaceutical company with intellectual property for drugs that treat autoimmune disorders, viral diseases and pain. Nutra Pharma was incorporated under the laws of the state of California on February 1, 2000, under the original name of Exotic-Bird.com. Nutra Pharma conducts drug discovery research and development (R&D) activities. In October 2009, Nutra Pharma launched its first consumer product called Cobroxin, an over-the-counter pain reliever designed to treat moderate to severe chronic pain. In May 2010, Nutra Pharma launched its second consumer product called Nyloxin, an over-the-counter pain reliever that is a stronger version of Cobroxin and is designed to treat severe chronic pain. In December 2014, we launched Pet Pain-Away, an over-the-counter pain reliever designed to treat pain in cats and dogs.
In its own words, from its 10-K, filed May 20, 2026.
Nutra Pharma against its Medicinal Chemicals & Botanical Products peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -59% against the peers' median +7%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| NPHC Nutra Pharma | Q2 2026 | $34K | -59% | n/m |
| CURLF Curaleaf Holdings | Q3 2026 | $353M | +11% | 0.8% |
| TLRY Tilray Brands | Q1 FY27 | $257M | +23% | -9.4% |
| TRLV Trulieve Cannabis | Q3 2026 | $230M | -20% | 18.5% |
| USNA Usana Health Sciences | Q2 2026 | $223M | -5% | -9.0% |
| AAWH Ascend Wellness Holdings | Q2 2026 | $126M | -0.9% | 4.2% |
| CRON Cronos Group | Q3 2026 | $83.9M | +72% | 10.8% |
| CGC Canopy Growth | Q2 FY27 | $71.1M | +20% | -23.1% |
| JUSH Jushi Holdings | Q3 2026 | $70.5M | +7% | 5.0% |
Source: Nutra Pharma 10-Q on SEC EDGAR · CIK 1119643 · Medicinal Chemicals & Botanical Products
More on NPHC
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results